Proxima Secures $80M Seed Round to Redefine Drug Discovery
January 17, 2026, 4:12 am
Location: United States, New Jersey, Lawrence
Employees: 10001+
Founded date: 1858
Location: United States, New Jersey, New Brunswick
Employees: 10001+
Founded date: 1886
Proxima, an AI-native biotech firm, secured an $80 million seed funding round. DCVC led the investment. NVentures and other major investors participated. Formerly VantAI, the company now targets proximity therapeutics. It aims to revolutionize drug discovery. Proxima addresses previously "undruggable" diseases. Its platform combines structural proteomics with advanced AI models. This capital fuels accelerated development. First-in-class medicines are in its sights. Programs focus on oncology and immunology. Significant biopharma collaborations are already active. Clinical trials are expected soon. Proxima heralds a new era of precision medicine.
Proxima, an AI-native biotech firm, has secured $80 million in seed funding. This significant investment positions the company at the forefront of a drug discovery revolution. DCVC spearheaded the funding round. NVentures, NVIDIA's venture arm, also joined. Braidwell, Roivant, AIX Ventures, Yosemite, Magnetic Ventures, Alexandria Venture Investments, and Modi Ventures contributed. Additional strategic and institutional backers participated. The capital influx underscores strong confidence in Proxima's vision.
The company, previously known as VantAI, rebranded to Proxima. This change emphasizes its singular focus. Proximity therapeutics define its core mission. Proxima aims to expand the druggable target space. It targets diseases once considered beyond reach.
Traditional small-molecule drugs often inhibit or activate single protein targets. Proxima’s approach is different. It controls protein-protein interactions. This alters biological outcomes. Proximity therapeutics induce, modulate, or block protein interfaces. This creates new pathways to combat disease. Molecular glues and PROTACs represent established modalities. Proxima extends beyond these. It explores emerging proximity-driven mechanisms. These new mechanisms broaden the scope of what is "druggable."
A central challenge in the field has been limited structural understanding. Protein-protein interactions drive most biological processes. Yet, only a small fraction are structurally characterized. The human interactome remains largely unmapped. This gap hinders reliable drug design. Proxima addresses this fundamental constraint.
Proxima's thesis is bold. It systematically generates structural data at scale. This data then pairs with purpose-built AI models. This combination enables reliable design of proximity-modulating molecules. It unlocks access to historically difficult targets.
Zachary Carpenter leads Proxima as CEO. He guides the company’s innovative strategy. Proxima's platform merges proteomics and machine learning. This generates novel therapeutic strategies. The goal is to make previously inaccessible targets viable. This offers new ways to treat complex diseases.
The new capital will accelerate Proxima's internal pipeline. It drives the development of first-in-class proximity-modulating therapeutics. The company will expand its capabilities across multiple disease areas. Oncology and immunology are primary targets. Additional therapeutic areas are also in focus.
Proxima also dedicates funds to foundational technology. It builds data layers for rational design. This supports current modalities. It also prepares for future waves of proximity-based medicines. Its technology aims for generalizability.
At the core of Proxima’s platform is NeoLink. This data-generation technology produces structural information. It operates at a proteome-wide scale. This creates a rich data layer. This data feeds Proxima’s Neo AI model series. These AI models enable end-to-end discovery. They support development of proximity-modulating small molecules.
The company states clear goals. It seeks to improve drug safety. It aims to shorten development timelines. It unlocks novel mechanisms of action. Researchers can intentionally induce, modulate, or block protein interfaces. This represents a paradigm shift.
Proxima also maintains a robust partner-facing business. It secured multibillion-dollar research collaborations. Major biopharmaceutical companies are partners. Johnson & Johnson, Bristol Myers Squibb, and Blueprint Medicines are among them. Blueprint Medicines was acquired by Sanofi. These collaborations validate Proxima's platform.
Multiple co-developed programs are advancing. They are progressing towards clinical trials. The first such program is expected to enter trials in 2026. This marks significant progress. It demonstrates the tangible impact of Proxima’s technology.
The rebrand to Proxima signals strategic intent. It underscores a dedicated focus. Proxima is building the necessary infrastructure. This scales proximity therapeutics. It moves them from bespoke successes to a repeatable paradigm.
Proxima builds a structural proteomics foundation. It trains frontier AI systems. These systems focus on protein complex data. The company aims for broad accessibility for proximity-based medicines. This transforms discovery and development. Jason Pontin, DCVC General Partner, joins Proxima's board. This adds strategic guidance.
Proxima's investment represents a key moment. It heralds significant advancements in drug discovery. The integration of AI with structural biology creates powerful tools. These tools tackle complex biological challenges. The promise is vast. New treatments for intractable diseases are on the horizon. The focus on protein interactions provides a new lens. It offers fresh approaches to medical intervention. Proxima aims to make these therapies widely available. It strives to transition them from rare exceptions to standard practice.
Proxima, an AI-native biotech firm, has secured $80 million in seed funding. This significant investment positions the company at the forefront of a drug discovery revolution. DCVC spearheaded the funding round. NVentures, NVIDIA's venture arm, also joined. Braidwell, Roivant, AIX Ventures, Yosemite, Magnetic Ventures, Alexandria Venture Investments, and Modi Ventures contributed. Additional strategic and institutional backers participated. The capital influx underscores strong confidence in Proxima's vision.
The company, previously known as VantAI, rebranded to Proxima. This change emphasizes its singular focus. Proximity therapeutics define its core mission. Proxima aims to expand the druggable target space. It targets diseases once considered beyond reach.
Traditional small-molecule drugs often inhibit or activate single protein targets. Proxima’s approach is different. It controls protein-protein interactions. This alters biological outcomes. Proximity therapeutics induce, modulate, or block protein interfaces. This creates new pathways to combat disease. Molecular glues and PROTACs represent established modalities. Proxima extends beyond these. It explores emerging proximity-driven mechanisms. These new mechanisms broaden the scope of what is "druggable."
A central challenge in the field has been limited structural understanding. Protein-protein interactions drive most biological processes. Yet, only a small fraction are structurally characterized. The human interactome remains largely unmapped. This gap hinders reliable drug design. Proxima addresses this fundamental constraint.
Proxima's thesis is bold. It systematically generates structural data at scale. This data then pairs with purpose-built AI models. This combination enables reliable design of proximity-modulating molecules. It unlocks access to historically difficult targets.
Zachary Carpenter leads Proxima as CEO. He guides the company’s innovative strategy. Proxima's platform merges proteomics and machine learning. This generates novel therapeutic strategies. The goal is to make previously inaccessible targets viable. This offers new ways to treat complex diseases.
The new capital will accelerate Proxima's internal pipeline. It drives the development of first-in-class proximity-modulating therapeutics. The company will expand its capabilities across multiple disease areas. Oncology and immunology are primary targets. Additional therapeutic areas are also in focus.
Proxima also dedicates funds to foundational technology. It builds data layers for rational design. This supports current modalities. It also prepares for future waves of proximity-based medicines. Its technology aims for generalizability.
At the core of Proxima’s platform is NeoLink. This data-generation technology produces structural information. It operates at a proteome-wide scale. This creates a rich data layer. This data feeds Proxima’s Neo AI model series. These AI models enable end-to-end discovery. They support development of proximity-modulating small molecules.
The company states clear goals. It seeks to improve drug safety. It aims to shorten development timelines. It unlocks novel mechanisms of action. Researchers can intentionally induce, modulate, or block protein interfaces. This represents a paradigm shift.
Proxima also maintains a robust partner-facing business. It secured multibillion-dollar research collaborations. Major biopharmaceutical companies are partners. Johnson & Johnson, Bristol Myers Squibb, and Blueprint Medicines are among them. Blueprint Medicines was acquired by Sanofi. These collaborations validate Proxima's platform.
Multiple co-developed programs are advancing. They are progressing towards clinical trials. The first such program is expected to enter trials in 2026. This marks significant progress. It demonstrates the tangible impact of Proxima’s technology.
The rebrand to Proxima signals strategic intent. It underscores a dedicated focus. Proxima is building the necessary infrastructure. This scales proximity therapeutics. It moves them from bespoke successes to a repeatable paradigm.
Proxima builds a structural proteomics foundation. It trains frontier AI systems. These systems focus on protein complex data. The company aims for broad accessibility for proximity-based medicines. This transforms discovery and development. Jason Pontin, DCVC General Partner, joins Proxima's board. This adds strategic guidance.
Proxima's investment represents a key moment. It heralds significant advancements in drug discovery. The integration of AI with structural biology creates powerful tools. These tools tackle complex biological challenges. The promise is vast. New treatments for intractable diseases are on the horizon. The focus on protein interactions provides a new lens. It offers fresh approaches to medical intervention. Proxima aims to make these therapies widely available. It strives to transition them from rare exceptions to standard practice.